Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead?

Core Insights - Eli Lilly's key revenue drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity, which together account for over 50% of total revenues [1][4][10] Product Performance - Mounjaro and Zepbound, both containing the compound tirzepatide, have seen exceptional sales growth, with Mounjaro leading in new prescriptions for type II diabetes and Zepbound capturing nearly 70% of the branded obesity market [2][3] - In 2025, Mounjaro and Zepbound generated combined sales of $36.5 billion, representing approximately 56% of Eli Lilly's total revenues [4][10] Competitive Landscape - Mounjaro and Zepbound face competition from Novo Nordisk's semaglutide products, Ozempic and Wegovy, but have outperformed them in sales and market share [3][10] - The global obesity drug market is projected to grow significantly, reaching nearly $95 billion by 2030 and potentially $125 billion by 2035, intensifying competition among major players [9] Future Growth Catalysts - New approvals for obesity-related conditions and the launch of lower-priced Zepbound doses are expected to drive further sales growth [5] - Eli Lilly plans to launch its oral GLP-1 pill, orforglipron, in the U.S. in the second quarter of 2026, which is anticipated to expand the addressable market [6][10] - The company is also expanding its incretin production capabilities to sustain growth amid rising competition [5][8] Market Access and Regulatory Developments - New Medicare access to obesity medicines is expected to accelerate adoption by July 2026, although Medicaid access may decrease in certain states [7] - Smaller biotech companies are also developing oral GLP-1 drugs, which could pose a threat to Lilly and Novo Nordisk's market dominance [11][13] Financial Performance and Valuation - Eli Lilly's stock has increased by 13.9% over the past year, outperforming the industry average of 12.8% [14] - The company's shares currently trade at a price/earnings ratio of 29.69, higher than the industry average of 18.69, but below its 5-year mean of 34.57 [15] - The Zacks Consensus Estimate for 2026 earnings per share has risen from $33.14 to $33.86 over the past 30 days, indicating positive market sentiment [19]